FDA Voucher Program Changes May Impact Cancer Drug Access Pathways

References

1. 1.Balasubramanian, G., Morampudi, S., Chhabra, P., Gowda, A., & Zomorodi, B. (2021). An analysis of FDA expanded access program: trends and outcomes over the years. Therapeutic Innovation & Regulatory Science, 55(2), 362-371. https://doi.org/10.1007/s43441-020-00245-9
2. 2.Chen, E. Y., Raghunathan, V., & Prasad, V. (2019). An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Internal Medicine, 179(7), 915-921. https://doi.org/10.1001/jamainternmed.2019.0583
3. 3.Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2020). FDA approval and regulation of pharmaceuticals, 1983-2018. JAMA, 323(2), 164-176. https://doi.org/10.1001/jama.2020.20288
4. 4.Eichler, H. G., Baird, L. G., Barker, R., Bloechl-Daum, B., Børlum-Kristensen, F., Brown, J., ... & Rasi, G. (2015). From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clinical Pharmacology & Therapeutics, 97(3), 234-246. https://doi.org/10.1002/cpt.59
5. 5.Hwang, T. J., Franklin, J. M., Chen, C. T., Lauffenburger, J. C., Gyawali, B., Kesselheim, A. S., & Darrow, J. J. (2016). Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines. Journal of Clinical Oncology, 34(29), 3511-3518. https://doi.org/10.1200/JCO.2016.67.4592
6. 6.Jarow, J. P., Lurie, P., Ikenberry, S. C., & Lemery, S. (2017). Overview of FDA's expanded access program for investigational drugs. Therapeutic Innovation & Regulatory Science, 51(2), 177-179. https://doi.org/10.1177/2168479016656027
7. 7.Keshavan, M. (2026, June 5). Will Makary's FDA voucher program survive? STAT News. https://www.statnews.com/2026/06/05/biotech-news-will-makarys-fda-voucher-program-survive/
8. 8.Liberti, L., Bujar, M., Breckenridge, A., Hoekman, J., McAuslane, N., Stolk, P., & Leufkens, H. (2017). FDA facilitated regulatory pathways: visualizing their characteristics, development, and authorization timelines. Frontiers in Pharmacology, 8, 161. https://doi.org/10.3389/fphar.2017.00161
9. 9.Ridley, D. B., Grabowski, H. G., & Moe, J. L. (2006). Developing drugs for developing countries. Health Affairs, 25(2), 313-324. https://doi.org/10.1377/hlthaff.25.2.313
10. 10.Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 233-254. https://doi.org/10.3322/caac.21763